Nazartinib; EGF816; NVS-816

Ingoa matū:

(R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)engari-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)- 2-methylisonicotinamide

Waehere SMILES:

O=C(NC1=NC2=CC=CC(Cl)=C2N1[C@H]3CN(C(/C=C/CN(C)C)=O)CCCC3)C4=CC=NC(C)= C4

Waehere InChi:

InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33( 26)20-8-4-5-15 -32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3 ,(H,29,30,35)/b11-7+/t20-/m1/s1

Kī InChi:

IOMMMLWIABWRKL-WUTDNEBXSA-N

Kupumatua:

Nazartinib ,EGF816, EGF-816, EGF 816, NVS-816, 1508250-71-2

Wairewa:Wairewa i roto i te DMSO

Rokiroki:0 - 4°C mo te wa poto (ra ki nga wiki), -20°C ranei mo te wa roa (marama)

Whakaahuatanga:

Ko te Nazartinib, e mohiotia ana ko EGF816 me te NVS-816, he aukati-waha, e kore e taea te whakahoki, tuatoru-whakatupuranga, mutant-selectective epidermal growth factor receptor (EGFR) inhibitor, me te mahi antineoplastic pea. Ko te EGF816 e herea ana me te aukati i te mahi o nga momo mutant o EGFR, tae atu ki te T790M EGFR mutant, na reira ka aukati i te tohu takawaenga EGFR. Ma tenei ka paheke te mate o te pūtau me te aukati i te tipu o te puku i roto i te EGFR-overexpressing pūtau puku. Ko te EGF816 he aukati i nga momo rerekee o te EGFR tae atu ki te T790M, he rerekeetanga parenga tuarua, a tera pea ka whai hua whakaora i roto i nga pukupuku me te aukati T790M-takawaenga ina whakaritea ki etahi atu aukati EGFR tyrosine kinase.

Whāinga: EGFR